Product  ||| S:0 E:8 ||| NN
evaluation  ||| S:8 E:19 ||| NN
of  ||| S:19 E:22 ||| IN
Ureadin  ||| S:22 E:30 ||| NNP
Rx  ||| S:30 E:33 ||| NNP
Db  ||| S:33 E:36 ||| NNP
( ||| S:36 E:37 ||| -LRB-
ISDIN ||| S:37 E:42 ||| NNP
)  ||| S:42 E:44 ||| -RRB-
for  ||| S:44 E:48 ||| IN
prevention  ||| S:48 E:59 ||| NN
and  ||| S:59 E:63 ||| CC
treatment  ||| S:63 E:73 ||| NN
of  ||| S:73 E:76 ||| IN
mild-to-moderate  ||| S:76 E:93 ||| JJ
xerosis  ||| S:93 E:101 ||| NN
of  ||| S:101 E:104 ||| IN
the  ||| S:104 E:108 ||| DT
foot  ||| S:108 E:113 ||| NN
in  ||| S:113 E:116 ||| IN
diabetic  ||| S:116 E:125 ||| JJ
patients ||| S:125 E:133 ||| NNS
.  ||| S:133 E:135 ||| .
Prevention  ||| S:135 E:146 ||| NN
of  ||| S:146 E:149 ||| IN
skin  ||| S:149 E:154 ||| NN
lesions  ||| S:154 E:162 ||| NNS
due  ||| S:162 E:166 ||| JJ
to  ||| S:166 E:169 ||| TO
microangiopathy  ||| S:169 E:185 ||| VB
The  ||| S:185 E:189 ||| DT
aim  ||| S:189 E:193 ||| NN
of  ||| S:193 E:196 ||| IN
this  ||| S:196 E:201 ||| DT
pilot ||| S:201 E:206 ||| NN
,  ||| S:206 E:208 ||| ,
registry  ||| S:208 E:217 ||| JJ
study  ||| S:217 E:223 ||| NN
was  ||| S:223 E:227 ||| VBD
to  ||| S:227 E:230 ||| TO
evaluate  ||| S:230 E:239 ||| VB
a  ||| S:239 E:241 ||| DT
dermatological  ||| S:241 E:256 ||| JJ
solution  ||| S:256 E:265 ||| NN
Ureadin  ||| S:265 E:273 ||| NNP
Rx  ||| S:273 E:276 ||| NNP
Db  ||| S:276 E:279 ||| NNP
( ||| S:279 E:280 ||| -LRB-
ISDIN ||| S:280 E:285 ||| NNP
)  ||| S:285 E:287 ||| -RRB-
including  ||| S:287 E:297 ||| VBG
urea  ||| S:297 E:302 ||| NN
in  ||| S:302 E:305 ||| IN
a  ||| S:305 E:307 ||| DT
water-lipid-based  ||| S:307 E:325 ||| JJ
foam  ||| S:325 E:330 ||| NN
delivery  ||| S:330 E:339 ||| NN
system  ||| S:339 E:346 ||| NN
in  ||| S:346 E:349 ||| IN
diabetic  ||| S:349 E:358 ||| JJ
subjects  ||| S:358 E:367 ||| NNS
with  ||| S:367 E:372 ||| IN
microangiopathy  ||| S:372 E:388 ||| NN
and  ||| S:388 E:392 ||| CC
with  ||| S:392 E:397 ||| IN
mild-to-moderate  ||| S:397 E:414 ||| JJ
xerosis  ||| S:414 E:422 ||| NN
of  ||| S:422 E:425 ||| IN
the  ||| S:425 E:429 ||| DT
foot ||| S:429 E:433 ||| NN
.  ||| S:433 E:435 ||| .
The  ||| S:435 E:439 ||| DT
product  ||| S:439 E:447 ||| NN
was  ||| S:447 E:451 ||| VBD
applied  ||| S:451 E:459 ||| VBN
to  ||| S:459 E:462 ||| TO
the  ||| S:462 E:466 ||| DT
whole  ||| S:466 E:472 ||| JJ
surface  ||| S:472 E:480 ||| NN
of  ||| S:480 E:483 ||| IN
the  ||| S:483 E:487 ||| DT
foot  ||| S:487 E:492 ||| NN
and  ||| S:492 E:496 ||| CC
particularly  ||| S:496 E:509 ||| RB
on  ||| S:509 E:512 ||| IN
the  ||| S:512 E:516 ||| DT
affected  ||| S:516 E:525 ||| JJ
areas  ||| S:525 E:531 ||| NNS
and  ||| S:531 E:535 ||| CC
pressure ||| S:535 E:543 ||| NN
/ ||| S:543 E:544 ||| CD
contact  ||| S:544 E:552 ||| NN
zones ||| S:552 E:557 ||| NNS
,  ||| S:557 E:559 ||| ,
at  ||| S:559 E:562 ||| IN
least  ||| S:562 E:568 ||| JJS
twice  ||| S:568 E:574 ||| RB
daily  ||| S:574 E:580 ||| JJ
for  ||| S:580 E:584 ||| IN
4  ||| S:584 E:586 ||| CD
weeks ||| S:586 E:591 ||| NNS
.  ||| S:591 E:593 ||| .
Skin  ||| S:593 E:598 ||| NN
breaks ||| S:598 E:604 ||| NNS
,  ||| S:604 E:606 ||| ,
ulcerations ||| S:606 E:617 ||| NN
,  ||| S:617 E:619 ||| ,
infection ||| S:619 E:628 ||| NN
,  ||| S:628 E:630 ||| ,
investigator  ||| S:630 E:643 ||| NN
and  ||| S:643 E:647 ||| CC
patients ||| S:647 E:655 ||| NNS
'  ||| S:655 E:657 ||| POS
questionnaire ||| S:657 E:670 ||| NN
,  ||| S:670 E:672 ||| ,
microcirculatory  ||| S:672 E:689 ||| JJ
measurements ||| S:689 E:701 ||| NNS
,  ||| S:701 E:703 ||| ,
skin  ||| S:703 E:708 ||| NN
thickness  ||| S:708 E:718 ||| NN
( ||| S:718 E:719 ||| -LRB-
ultrasound ||| S:719 E:729 ||| LS
) ||| S:729 E:730 ||| -RRB-
,  ||| S:730 E:732 ||| ,
laser  ||| S:732 E:738 ||| FW
Doppler  ||| S:738 E:746 ||| FW
flux  ||| S:746 E:751 ||| FW
and  ||| S:751 E:755 ||| CC
other  ||| S:755 E:761 ||| JJ
parameters  ||| S:761 E:772 ||| NNS
were  ||| S:772 E:777 ||| VBD
observed  ||| S:777 E:786 ||| VBN
and  ||| S:786 E:790 ||| CC
evaluated  ||| S:790 E:800 ||| VBN
at  ||| S:800 E:803 ||| IN
inclusion  ||| S:803 E:813 ||| NN
and  ||| S:813 E:817 ||| CC
4  ||| S:817 E:819 ||| CD
weeks ||| S:819 E:824 ||| NNS
.  ||| S:824 E:826 ||| .
The  ||| S:826 E:830 ||| DT
evaluation  ||| S:830 E:841 ||| NN
in  ||| S:841 E:844 ||| IN
skin  ||| S:844 E:849 ||| NN
breaks  ||| S:849 E:856 ||| NNS
indicated  ||| S:856 E:866 ||| VBD
a  ||| S:866 E:868 ||| DT
decrease  ||| S:868 E:877 ||| NN
in  ||| S:877 E:880 ||| IN
breaks  ||| S:880 E:887 ||| NNS
in  ||| S:887 E:890 ||| IN
the  ||| S:890 E:894 ||| DT
Ureadin  ||| S:894 E:902 ||| JJ
group  ||| S:902 E:908 ||| NN
vs  ||| S:908 E:911 ||| NN
controls  ||| S:911 E:920 ||| NNS
( ||| S:920 E:921 ||| -LRB-
p  ||| S:921 E:922 ||| CD
< ||| S:922 E:923 ||| SYM
0.05 ||| S:923 E:927 ||| CD
)  ||| S:927 E:929 ||| -RRB-
with  ||| S:929 E:934 ||| IN
the  ||| S:934 E:938 ||| DT
development  ||| S:938 E:950 ||| NN
of  ||| S:950 E:953 ||| IN
one  ||| S:953 E:957 ||| CD
ulcer  ||| S:957 E:963 ||| NN
in  ||| S:963 E:966 ||| IN
controls ||| S:966 E:974 ||| NNS
.  ||| S:974 E:976 ||| .
There  ||| S:976 E:982 ||| EX
was  ||| S:982 E:986 ||| VBD
a  ||| S:986 E:988 ||| DT
significant  ||| S:988 E:1000 ||| JJ
difference  ||| S:1000 E:1011 ||| NN
in  ||| S:1011 E:1014 ||| IN
favour  ||| S:1014 E:1021 ||| NN
of  ||| S:1021 E:1024 ||| IN
the  ||| S:1024 E:1028 ||| DT
Ureadin  ||| S:1028 E:1036 ||| JJ
group  ||| S:1036 E:1042 ||| NN
in  ||| S:1042 E:1045 ||| IN
both  ||| S:1045 E:1050 ||| PDT
the  ||| S:1050 E:1054 ||| DT
Investigator  ||| S:1054 E:1067 ||| JJ
global  ||| S:1067 E:1074 ||| JJ
assessment  ||| S:1074 E:1085 ||| NN
and  ||| S:1085 E:1089 ||| CC
in  ||| S:1089 E:1092 ||| IN
the  ||| S:1092 E:1096 ||| DT
subjects ||| S:1096 E:1104 ||| NNS
'  ||| S:1104 E:1106 ||| POS
assessment  ||| S:1106 E:1117 ||| NN
questionanire  ||| S:1117 E:1131 ||| NNS
( ||| S:1131 E:1132 ||| -LRB-
p  ||| S:1132 E:1133 ||| CD
< ||| S:1133 E:1134 ||| SYM
0.05 ||| S:1134 E:1138 ||| CD
) ||| S:1138 E:1139 ||| -RRB-
.  ||| S:1139 E:1141 ||| .
At  ||| S:1141 E:1144 ||| IN
4  ||| S:1144 E:1146 ||| CD
weeks  ||| S:1146 E:1152 ||| NNS
PO2  ||| S:1152 E:1156 ||| RB
was  ||| S:1156 E:1160 ||| VBD
improved  ||| S:1160 E:1169 ||| VBN
in  ||| S:1169 E:1172 ||| IN
the  ||| S:1172 E:1176 ||| DT
Ureadin  ||| S:1176 E:1184 ||| JJ
group  ||| S:1184 E:1190 ||| NN
( ||| S:1190 E:1191 ||| -LRB-
p  ||| S:1191 E:1192 ||| CD
< ||| S:1192 E:1193 ||| SYM
0.05 ||| S:1193 E:1197 ||| CD
)  ||| S:1197 E:1199 ||| -RRB-
and  ||| S:1199 E:1203 ||| CC
PCO2  ||| S:1203 E:1208 ||| NNP
was  ||| S:1208 E:1212 ||| VBD
significantly  ||| S:1212 E:1226 ||| RB
better  ||| S:1226 E:1233 ||| JJR
( ||| S:1233 E:1234 ||| -LRB-
p  ||| S:1234 E:1235 ||| CD
< ||| S:1235 E:1236 ||| SYM
0.05 ||| S:1236 E:1240 ||| CD
)  ||| S:1240 E:1242 ||| -RRB-
in  ||| S:1242 E:1245 ||| IN
the  ||| S:1245 E:1249 ||| DT
Ureadin  ||| S:1249 E:1257 ||| JJ
group ||| S:1257 E:1262 ||| NN
.  ||| S:1262 E:1264 ||| .
Skin  ||| S:1264 E:1269 ||| NN
thickness  ||| S:1269 E:1279 ||| NN
was  ||| S:1279 E:1283 ||| VBD
increased  ||| S:1283 E:1293 ||| VBN
( ||| S:1293 E:1294 ||| -LRB-
p  ||| S:1294 E:1295 ||| CD
< ||| S:1295 E:1296 ||| SYM
0.05 ||| S:1296 E:1300 ||| CD
)  ||| S:1300 E:1302 ||| -RRB-
in  ||| S:1302 E:1305 ||| IN
the  ||| S:1305 E:1309 ||| DT
Ureadin  ||| S:1309 E:1317 ||| JJ
group  ||| S:1317 E:1323 ||| NN
( ||| S:1323 E:1324 ||| -LRB-
no  ||| S:1324 E:1327 ||| DT
change  ||| S:1327 E:1334 ||| NN
in  ||| S:1334 E:1337 ||| IN
controls ||| S:1337 E:1345 ||| NNS
)  ||| S:1345 E:1347 ||| -RRB-
indicating  ||| S:1347 E:1358 ||| VBG
a  ||| S:1358 E:1360 ||| DT
better  ||| S:1360 E:1367 ||| JJR
hydration  ||| S:1367 E:1377 ||| NN
of  ||| S:1377 E:1380 ||| IN
the  ||| S:1380 E:1384 ||| DT
more  ||| S:1384 E:1389 ||| RBR
superficial  ||| S:1389 E:1401 ||| JJ
skin  ||| S:1401 E:1406 ||| NN
layers ||| S:1406 E:1412 ||| NNS
.  ||| S:1412 E:1414 ||| .
Skin  ||| S:1414 E:1419 ||| NN
flux  ||| S:1419 E:1424 ||| NN
and  ||| S:1424 E:1428 ||| CC
the  ||| S:1428 E:1432 ||| DT
venoarteriolar  ||| S:1432 E:1447 ||| JJ
response  ||| S:1447 E:1456 ||| NN
were  ||| S:1456 E:1461 ||| VBD
better  ||| S:1461 E:1468 ||| RB
improved  ||| S:1468 E:1477 ||| VBN
in  ||| S:1477 E:1480 ||| IN
the  ||| S:1480 E:1484 ||| DT
Ureadin  ||| S:1484 E:1492 ||| JJ
group ||| S:1492 E:1497 ||| NN
.  ||| S:1497 E:1499 ||| .
Considering  ||| S:1499 E:1511 ||| VBG
new  ||| S:1511 E:1515 ||| JJ
skin  ||| S:1515 E:1520 ||| NN
lesions  ||| S:1520 E:1528 ||| NNS
at  ||| S:1528 E:1531 ||| IN
4  ||| S:1531 E:1533 ||| CD
weeks  ||| S:1533 E:1539 ||| NNS
there  ||| S:1539 E:1545 ||| EX
were  ||| S:1545 E:1550 ||| VBD
no  ||| S:1550 E:1553 ||| DT
Class  ||| S:1553 E:1559 ||| NN
A  ||| S:1559 E:1561 ||| DT
lesions  ||| S:1561 E:1569 ||| NN
in  ||| S:1569 E:1572 ||| IN
the  ||| S:1572 E:1576 ||| DT
Ureadin  ||| S:1576 E:1584 ||| JJ
group  ||| S:1584 E:1590 ||| NN
vs.  ||| S:1590 E:1594 ||| IN
4  ||| S:1594 E:1596 ||| CD
lesions  ||| S:1596 E:1604 ||| NNS
in  ||| S:1604 E:1607 ||| IN
26  ||| S:1607 E:1610 ||| CD
patients  ||| S:1610 E:1619 ||| NNS
( ||| S:1619 E:1620 ||| -LRB-
15.38 ||| S:1620 E:1625 ||| NNP
% ||| S:1625 E:1626 ||| NN
;  ||| S:1626 E:1628 ||| :
p  ||| S:1628 E:1629 ||| CD
< ||| S:1629 E:1630 ||| SYM
0.05 ||| S:1630 E:1634 ||| CD
)  ||| S:1634 E:1636 ||| -RRB-
in  ||| S:1636 E:1639 ||| IN
the  ||| S:1639 E:1643 ||| DT
control  ||| S:1643 E:1651 ||| NN
group ||| S:1651 E:1656 ||| NN
.  ||| S:1656 E:1658 ||| .
There  ||| S:1658 E:1664 ||| EX
was  ||| S:1664 E:1668 ||| VBD
also  ||| S:1668 E:1673 ||| RB
a  ||| S:1673 E:1675 ||| DT
Class  ||| S:1675 E:1681 ||| NNP
B  ||| S:1681 E:1683 ||| NNP
lesion  ||| S:1683 E:1690 ||| NNS
( ||| S:1690 E:1691 ||| -LRB-
3.84 ||| S:1691 E:1695 ||| CD
% ||| S:1695 E:1696 ||| NN
;  ||| S:1696 E:1698 ||| :
p  ||| S:1698 E:1699 ||| CD
< ||| S:1699 E:1700 ||| SYM
0.05 ||| S:1700 E:1704 ||| CD
)  ||| S:1704 E:1706 ||| -RRB-
in  ||| S:1706 E:1709 ||| IN
controls ||| S:1709 E:1717 ||| NNS
.  ||| S:1717 E:1719 ||| .
Diabetic  ||| S:1719 E:1728 ||| JJ
control  ||| S:1728 E:1736 ||| NN
was  ||| S:1736 E:1740 ||| VBD
good  ||| S:1740 E:1745 ||| JJ
( ||| S:1745 E:1746 ||| -LRB-
as  ||| S:1746 E:1749 ||| RB
before  ||| S:1749 E:1756 ||| IN
inclusion  ||| S:1756 E:1766 ||| NN
and  ||| S:1766 E:1770 ||| CC
did  ||| S:1770 E:1774 ||| VBD
not  ||| S:1774 E:1778 ||| RB
change  ||| S:1778 E:1785 ||| VB
at  ||| S:1785 E:1788 ||| IN
4  ||| S:1788 E:1790 ||| CD
weeks ||| S:1790 E:1795 ||| NNS
) ||| S:1795 E:1796 ||| -RRB-
.  ||| S:1796 E:1798 ||| .
Therefore  ||| S:1798 E:1808 ||| RB
the  ||| S:1808 E:1812 ||| DT
clinical  ||| S:1812 E:1821 ||| JJ
and  ||| S:1821 E:1825 ||| CC
microcirculatory  ||| S:1825 E:1842 ||| JJ
changes  ||| S:1842 E:1850 ||| NNS
were  ||| S:1850 E:1855 ||| VBD
very  ||| S:1855 E:1860 ||| RB
possibly  ||| S:1860 E:1869 ||| RB
due  ||| S:1869 E:1873 ||| JJ
only  ||| S:1873 E:1878 ||| JJ
to  ||| S:1878 E:1881 ||| TO
local  ||| S:1881 E:1887 ||| JJ
management  ||| S:1887 E:1898 ||| NN
and  ||| S:1898 E:1902 ||| CC
not  ||| S:1902 E:1906 ||| RB
to  ||| S:1906 E:1909 ||| TO
a  ||| S:1909 E:1911 ||| DT
systemic  ||| S:1911 E:1920 ||| JJ
improvement  ||| S:1920 E:1932 ||| NN
in  ||| S:1932 E:1935 ||| IN
the  ||| S:1935 E:1939 ||| DT
management  ||| S:1939 E:1950 ||| NN
of  ||| S:1950 E:1953 ||| IN
diabetes ||| S:1953 E:1961 ||| NN
.  ||| S:1961 E:1963 ||| .
